Home > Analyse
Actualite financiere : Actualite bourse

Sanofi: successful trial on dupilumab.

(CercleFinance.com) - Sanofi has announced that the phase 3 experimental study evaluating dupilumab for the treatment of a severe steroid-dependent asthma population has met its primary endpoint and key secondary endpoints.

At 24 weeks, dupilumab added to standard therapies significantly reduced the use of maintenance oral corticosteroids, (OCS) by 70% on average, compared to 42% with placebo.

Sanofi stresses that this is the first pivotal clinical program to demonstrate the consistent role of a biological agent in reducing asthma attacks and improving respiratory function in a large population of patients suffering from uncontrolled asthma.

Copyright (c) 2017 CercleFinance.com. All rights reserved.